another malignancy, another disease, or accident were treated as censored cases in the survival analysis. Twenty-one patients whose causes of death were unknown and 45 patients who died of postoperative complications were excluded from the prognostic analysis.
Statistical analysis
The association between factors was evaluated by the χ 2 test and Fisher's exact probability test. The significance of differences among means was determined by the Mann-Whitney test. Survival rates were determined by the Kaplan-Meier method, and differences between survival curves were examined with the log-rank test. The accepted level of signifi cance was P < 0.05. Stat View software (Abacus Concepts, Berkeley, CA, USA) was used for all statistical analyses.
Results
Of 313 patients with metastasis in group 2 lymph nodes (LNs), 21 patients (6.7%) did not have metastasis in group 1 LNs. The profi les of the 21 patients with skip LN metastases are shown in Table 1 . Nine patients had metastasis in the LN along the common hepatic artery (No. 8a), 8 The clinicopathological data of the patients with skip metastasis were compared with the data of those with metastasis in only group 1 nodes (N1, 348 patients) and those with metastasis in both group 1 and 2 nodes (N2, 292 patients; Table 2 ). The mean size (±SD) of tumors in patients with skip metastasis was 5.7 ± 2.4 cm, which was signifi cantly smaller than those in N1 patients (7.9 ± 4.1 cm) and N2 patients (9.3 ± 4.6 cm). The incidence of serosal invasion was 38.1% for patients with skip metastasis, which was signifi cantly lower than that for N1 patients (56.7%) and N2 patients (78.4%). Lymphatic vessel invasion was less frequent in patients with skip metastasis (81.0%) compared with N2 patients (93.2%). The incidence of peritoneal metastasis was The disease-specifi c survival of the patients, according to the status of LN metastasis, defi ned by the Japanese Classifi cation of Gastric Carcinoma [7] , is illustrated in Fig. 1A . The 5-year survival rates were 70.2%, 62.0%, and 31.2% in patients with skip metastasis, metastasis in group 1 LNs, and metastasis in group 2 LNs, respectively. The prognosis of patients with metastasis in group 2 LNs was signifi cantly worse than that of the patients with either skip metastasis (P = 0.0029) or metastasis in group 1 LNs (P < 0.0001). Figure 1B shows the disease-specifi c survival of the patients according to the status of LN metastasis defi ned by the TNM classifi cation. The 5-year survival rates were 70.2%, 60.6%, and 27.3% in patients with skip metastasis, those with N1, and those with N2, respectively. The prognosis of patients with N2 was signifi cantly worse than that of patients with either skip metastasis (P = 0.0002) or N1 (P < 0.0001).
Discussion
Evaluation of the status of LN metastasis is extremely important to predict the outcome of patients with many kinds of cancer, including gastric cancer. Gastric cancer has been assumed to spread sequentially through the anatomical regional lymphatic bed. In the current study, however, 21 patients (6.7%) had skip metastasis.
Skip metastasis can be explained by nonsequential spread through the lymphatic basin, or nonanatomical spread. The results of sentinel LN biopsy provide some important information. Sentinel LN biopsy has recently been introduced in patients with melanoma and breast cancer to assess tumor involvement in regional LNs; the procedure has less morbidity than but accuracy equal to that of complete lymphadenectomy [8] [9] [10] [11] [12] . The sentinel node concept is that LN metastases spread in an orderly fashion in relation to the lymphatic streams, and that the negative tumor-bearing status of the fi rst LN into which the primary tumor drains indicates the negative tumor status of the entire region of LNs beyond. Ichikura et al. [13] , using indocyanine green solution, reported that green nodes, indicating sentinel LNs, were distributed beyond the perigastric area in 31% of patients. Kitagawa et al. [14] also reported that approximately one-third of the radioactive tracer they used was directly distributed to the group 2 LNs, and seven patients (5.1%) had skip sentinel nodes. These results indicate that the anatomical nodal grouping in the conventional classifi cation does not always correspond to tumor spread. There is another possibility that metastasis cannot be detected because of either an overlooking of the metastasis or the presence of micrometastasis, although metastasis does exist in group 1 LNs, indicating sequential anatomical LN metastasis. In this regard, Natsugoe et al. [15] demonstrated that, with a single-section examination of dissected nodes, metastasis could be overlooked in many cases in patients with gastric cancer. On the other hand, recent molecular techniques allow the detection of micrometastases. In this regard, we [16] found, by immunohistochemistry using anti-cytokeratin (CK) monoclonal antibody, that 2 of 83 patients with stage II gastric cancer (pT3N0M0) had only group 2 LN metastasis. Arai et al. [17] demonstrated, with CK staining of level I nodes from 7 patients thought to have skip metastasis, that although all patients were negative with hematoxylin and eosin staining, three were CK-positive. On the other hand, Merrie et al. [5] demonstrated a higher incidence of skip metastasis in colon cancer, assessed by molecular techniques, than has previously been reported. More extensive study is needed to determine the exact frequency of skip metastasis in gastric cancer.
The Japanese Classifi cation of Gastric Carcinoma (JCGC) defi nes N stage by the location of LN metastasis relative to the primary tumor [7] . On the other hand, the Union Internationale Contre le Cancer (UICC) defi nes N stage by the number of LN metastases. In the current study, we used the N stage defi ned by the JCGC and found that the clinicopathological characteristics of patients with skip metastasis were similar to those of patients with group 1 LN metastasis, but not to those of patients with group 2 LN metastasis. Moreover, the prognosis of patients with skip metastasis was similar to that of patients with group 1 LN metastasis and was signifi cantly better than that of patients with group 2 LN metastasis. Park et al. [18] also reported better prognosis of patients with skip metastasis compared to that of patients with group 2 LN metastasis, although the difference was not statistically signifi cant. Of importance is that all but 1 of the 21 patients with skip metastasis in the current study had only one or two positive nodes, and therefore they were classifi ed as N1 by the TNM classification, although they were classifi ed as N2 by the JCGC. Although it still remains elusive as to which is important, the location or the number of positive LNs, some studies indicate that the number-based N staging has greater prognostic power than the anatomical-based system [19] . Our results may also support the prognostic reliability of the current UICC/AJCC (American Joint Committee on Cancer) TNM staging system, in which LN status is evaluated by the number of positive nodes, and not by the topographical station, as in the JCGC. No. at risk Fig. 1 . A Disease-specifi c survival of the patients according to the status of lymph node metastasis defi ned by the Japanese Classifi cation of Gastric Carcinoma [7] . The 5-year survival rates were 70.2%, 62.0%, and 31.2% in patients with skip metastasis (skip meta), patients with metastasis in group 1 lymph nodes (N1), and those with metastasis in group 2 lymph nodes (N2), respectively. The prognosis of patients with metastasis in group 2 lymph nodes was signifi cantly worse than that of patients with either skip metastasis (P = 0.0029) or metastasis in group 1 lymph nodes (P < 0.0001). B Diseasespecifi c survival of the patients according to the status of lymph node metastasis defi ned by the TNM classifi cation. The 5-year survival rates were 70.2%, 60.6%, and 27.3% in patients with skip metastasis, those with N1, and those with N2, respectively. The prognosis of patients with N2 was significantly worse than that of the patients with either skip metastasis (P = 0.0002) or N1 (P < 0.0001)
In conclusion, our data indicate that both the clinicopathological characteristics and the prognoses of patients with skip metastasis were similar to these parameters in patients with group 1 LN metastasis, but not in patients with group 2 LN metastasis. The sites of skip metastasis presented in the current study may be the key for applying the concept of the sentinel node in gastric cancer.
